Brain dopamine receptors mediate a number of biochemical and behavioral effects in experimental animals (1-4). Alterations of dopamine-receptor activity in the brain are in all probability related to some clinical manifestations of parkinsonism and the effects of neuroleptic drugs in schizophrenia.
the major antipsychotic drugs, all of which block D-2 receptors at very low drug concentrations (7) . On the basis of this evidence and the results of receptor binding analyses of brain material from deceased schizophrenic patients, it has been proposed that some schizophrenic disorders may be related to an abnormal increase of central D-2 receptors (8, 9) .
Evaluation of these ideas concerning the mechanism of action of antipsychotic drugs and the pathophysiology of schizophrenia would be greatly facilitated by the development of in vivo methods to characterize D-2 receptors in the brains of healthy subjects and schizophrenic patients before and in relation to drug treatment. The development of highaffinity ligand binding techniques and positron emission tomography (PET) suggests the feasibility of such measurements. The combination of these techniques has recently been successfully used for the visualization of central dopamine receptors in the brains of monkeys and humans (10) (11) (12) (13) . The type of ligand used in previous PET studies on dopamine receptors, although having a high affinity for D-2 receptors, has also been shown to bind to central 5-HT-2 (5-hydroxytryptamine 2) receptors, D-1 receptors, and spirodecanone sites (7, (14) (15) (16) .
In the present study, we have explored the possibility of using another series of dopamine receptor antagonists as more selective ligands for D-2 receptor populations in the living human brain. Substituted benzamides like sulpiride have a high affinity for central D-2 receptors but are almost completely devoid of activity with regard to D-1, 5-HT-2, and other putative central receptors (17) . A new series of potent benzamide analogues was recently developed by Astra Lakemedel in Sweden (18, 19) . Some of these analogues have very high affinities-(Kd '-10-9 M) for central D-2 receptors (e.g., see Table 1 ) with negligible effects on other receptors (20) . These potent antidopaminergic effects have been confirmed by using in vivo receptor binding methods (21) as well as in behavioral studies (ref. 22 ; Table 1 ). The chemical structures of these compounds allow the rapid labeling of the molecules with "1C for PET-scan studies (23, 24) . Preliminary PET studies indicated that such compounds may be excellent tools for studies on central D-2 receptor populations in primates**. Here we describe experiments with two of these compounds, FLB 524 and raclopride (Fig. 1) . Kinetics of the in vivo binding of the "C-labeled ligands to various brain regions of monkeys and human subjects were analyzed. The specificity and reversibility of binding was studied in displacement experiments.
MATERIAL AND METHODS
Preparation of "C-Labeled Alkylating Agents 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. each. The animals were anaesthetized with ketamine (Ketalar, Parke-Davis; 10 mg/kg per hr, i.v.). CT scans of the brain adjusted to the cantomeatal plane were taken with 6.5-mm spacing. After the CT scans had been taken, the animal was placed in the positron camera. An intravenous cannula was inserted into the sural vein of one leg and, in most experiments, an intraarterial catheter was placed into the femoral artery of the other leg. During the experiment, body temperature was maintained at 36.5-37.0°C by means of two heating pads. The ligand, dissolved in about 5 ml of isotonic saline solution, was administered by intravenous bolus injection during about 10 sec. The radioactivity in the brain was followed by sequential PET scans during the next 40-70 min. Radioactivity in the blood was measured in blood samples drawn at regular intervals.
Experiments in Human Subjects. Five men aged 26-33 yr were examined. Physical examination, routine laboratory tests, and anamnestic information indicated that the subjects were physically and mentally healthy. CT scans with 6.5-mm spacing were obtained. On the following day, the subject was placed recumbent with his head in the PET camera system. Two venous cannulae were inserted into the antecubital veins. In some experiments an arterial cannula was inserted into the brachial artery. A solution of the ligand was injected intravenously as a bolus during 10 sec. Blood was drawn from the contralateral vein or the arterial catheter and PETscan pictures were obtained according to a preprogrammed sequence as described above. Activity was followed for 40-70 min.
RESULTS
Monkey Experiments with ["C]FLB 524. After the i.v. injection of ["C]FLB 524 (1.5 mCi, 50 Ci/mmol) to a first monkey, the radioactivity in blood reached a peak within 3 min and subsequently declined (Fig. 2) . The activity in cerebellum and striatum reached maximal levels within 7 and 20 min, respectively. In the cerebellum, after about 20 min, the activity declined with a half-life of -30 min. In the striatum the activity remained at the peak level for at least 60 min. After 20 min, the dopamine-rich corpus striatum showed up in PET-scan images as having higher activity than the rest of the brain. The activity ratio between the dopamine receptorrich striatum and the dopamine receptor-poor cerebellum is generally used as a measure of the relation between specific and nonspecific dopamine receptor binding (10, (27) (28) (29) (30) In an experiment in a second monkey, the specificity and reversibility of ["CJFLB 524 binding in the striatum was examined.
[11C]FLB 524 (10 mCi, 149 Ci/mmol) was injected i.v., and 30 min later haloperidol (2 mg/kg) was injected i.v. Prior to the haloperidol injection, the regional activity followed a time course similar to that described above for the first monkey. After the haloperidol injection, there was a deflection in the course of the striatal curve but not of the cerebellar curve. As a result, the ratio of striatal to cerebellar binding was reduced from 1.5, immediately prior to the haloperidol injection, to 1. was injected i.v. With this ligand, also, activity rapidly appeared in the brain. Striatal activity was higher than cerebellar activity from the first minute after the injection. The ratio of striatal to cerebellar activity rose during the following 20 min to a value of about 4 and continued to increase during the rest of the experiment (62 min).
In a second monkey, two experiments were carried out on the same day. In the morning, a control experiment with
[t1C]raclopride (5 mCi, 50 Ci/mmol) was performed (Fig. 3 Upper). The curves followed about the same course as in the experiment described above. In the afternoon, a displacement experiment was performed. All conditions were the same except that haloperidol (3 mg/kg) was injected i.v. 6 min after the tracer (Fig. 3 Lower) . The entire cerebellar curve was similar to that seen in the morning. During the first 6 min after ['1Clraclopride injection, the striatal curve followed a course similar to that seen in the morning experiment. Subsequent to the administration of haloperidol, the striatal curve was markedly deflected, approaching the cerebellar curve, which it reached about 16 min after the haloperidol injection. Immediately after the injection of haloperidol, activity in the blood rose slightly and subsequently stayed on a higher level than in the morning experiment, indicating displacement of the ligand from specific binding sites and its reappearance in the blood.
In a third monkey, the displacement experiment was repeated with a lower dose of haloperidol.
[ C]Raclopride (1 mCi, 30 Ci/mmol) was injected i.v.; 10 min later, haloperidol (2 mg/kg) was given i.v. During the initial phase (i.e., before haloperidol) the activity curves for the striatum and cerebellum were very similar to those described in the first two monkey experiments. In this experiment, there was also a marked displacement of the striatal curve in response to haloperidol administration. Thus, the striatal activity decreased, reaching the cerebellar level 26 min after the haloperidol injection. The amount of injected radioactivity varied from 3 to 4 mCi and the specific activity was between 40 and 110 Ci/mmol. Similar results were obtained in all five subjects. Fig. 4 shows the time course for the normalized average radioactivity in striatum (caudate nucleus, putamen) and cerebellum in the five subjects after the i.v. injection of ["C]raclopride.
In the caudate/putamen, maximal activity was reached after 20-30 min. In the cerebellum, the activity reached a peak within 5 min and then declined to a level that was less than one-third that of the striatal activity. The radioactivity in venous blood peaked within 2 min and then declined, following a course similar to that in cerebellum but at a slightly higher level. After 20 min the ratio of striatal to cerebellar activity was about 3. It increased to about 5 during the remainder of the experiment.
In these five subjects, no region of the brain other than caudate/putamen showed any conspicuous accumulation of radioactivity. The frontal cortex of rats has been claimed to contain a low but significant density of dopamine D-2 receptors (31). DISCUSSION The purpose of this study was to find selective high-affinity ligands with low nonspecific-binding properties for quantitative PET-scan studies on dopamine D-2 receptors in the living human brain. For a number of reasons, it was of interest to examine substituted benzamides in this regard. Several compounds of this type are selective and potent antagonists of central D-2 receptors in the rat brain (17, 20, 21) . The compounds selected for the present experiments, FLB 524 and raclopride, belong to a recently developed series of substituted benzamides (18, 19, 22) . In vitro receptor binding assays have demonstrated these compounds to be very po- (Fig. 3) . This result supports the view that haloperidol and raclopride compete for the same Proc. Nad Acad ScL USA 82 (1985) receptor is one of the criteria required for claiming that a ligand interacts with a specific receptor site (32) . This criterion accordingly seems to be fulfilled for [ 10, 11, 13) . The low nonspecific binding in the cerebellum with activity levels below the plasma level is an advantage that may be attributable at least partly to the relatively low lipid solubility of raclopride. Peak activity in the caudate/putamen was reached within 20-30 min, a feature also advantageous for further quantitative studies. For spiperone, the maximal ratio of striatal to cerebellar activity was not reached until several hours after injection (11) . Preliminary studies of saturation kinetics in healthy volunteers support the view that striatal binding is saturable and indicate the possibility of further quantitative analyses (unpublished observations).
Several clinical applications for the type of ligand developed in the present investigation can be envisaged. The anatomical structures of the caudate nucleus/putamen complex could be beautifully delineated in PET-scan images. CT-and PET-scan pictures from the same brain slice directly demonstrated the congruence of CT and PET images of the caudate/putamen (Fig. 5) . Even with the fairly low-resolution camera system used in the present study, the border between the caudate nucleus and the putamen can be observed in most subjects. Most intriguing is the potential for developing methods for the quantitative analysis of D-2 dopamine receptor characteristics in different brain regions in patients with neuropsychiatric disorders. Such studies seem pertinent in light of current hypotheses of the possible alteration of the D-2-receptor density in the basal ganglia of some schizophrenic patients (9) . Another potential of the technique has a similar clinical relevance. All hitherto developed antipsychotic drugs interfere with central D-2 receptors (7, 17 
